Citizens and Mizuho reaffirm positive ratings for Zscaler, highlighting its formidable competitive advantages rooted in complex implementation and high switching costs that lock in enterprise clients.
TD Cowen lowered its price target on Atlassian (TEAM) ahead of earnings, highlighting strong fundamentals in service management and cloud migration but flagging weak traction in AI as a key medium-term overhang for the stock.
Goldman Sachs initiates coverage on Workday with a Neutral rating, citing a crowded core market and a slower-than-expected AI strategy rollout. The firm identifies 2026 as a pivotal year for the HR and finance software giant to prove its technological evolution.
A combination of deep political polarization, economic pressures, and a growing brain drain is challenging Israel's viability as a secure and prosperous state, according to experts within and outside the country.
Compass Point initiates coverage on Orchid Island Capital (ORC) with a Neutral rating, citing concerns that the REIT's high dividend payouts could constrain its per-share book value appreciation despite its current undervaluation.
B. Riley initiates coverage of Adamas Trust (ADAM) with a Buy rating and a $9 price target, citing the REIT's strategic portfolio pivot towards higher-quality Agency RMBS as a key driver for potential revaluation.
Despite a cautious 'Moderate Sell' consensus, Paramount Skydance (PSKY) carries an average price target of $14.08, implying significant potential upside. The media giant's recent Q3 2025 results highlighted robust Paramount+ subscriber growth, even as investors weigh heavy content investments and integration risks.
Shares of NCR Voyix (VYX) saw a modest uptick this week, yet the broader picture remains challenging. With a significant decline over the past year and a net loss reported on substantial revenue, investors are questioning if the current valuation gap represents a genuine opportunity or a reflection of deeper issues.
Investment firm TD Cowen has significantly increased its price target for semiconductor equipment leader ASML Holding, citing robust bookings for its cutting-edge EUV lithography systems and a clear path for capacity expansion to meet relentless AI-driven demand.
Mizuho Securities raised its rating on Applied Materials (AMAT) to Outperform, with a $370 price target, forecasting accelerated growth in global wafer fab equipment spending driven by major chipmakers' capital expenditure plans.
Ziff Davis (ZD) shares show signs of a recent rebound, posting double-digit gains over the last quarter. Yet, a steep annual decline leaves investors questioning if the digital media firm is undervalued or facing structural headwinds. We break down the valuation debate and key risks.
While fintech has streamlined user interfaces, the backbone of finance remains slow. Cryptocurrency's native digital settlement presents a structural shift. Amid regulatory uncertainty, Cantor Fitzgerald identifies three public companies positioned to bridge the gap between traditional finance and the blockchain ecosystem.
At its Perform conference, Dynatrace unveiled Dynatrace Intelligence, a new platform merging deterministic and agentic AI to automate complex IT operations. The launch, coupled with enhanced cloud integrations and user monitoring tools, signals the company's aggressive push to dominate the observability market in an AI-driven era, even as some debate its current market valuation.
Investment bank Macquarie has raised its rating on NIO Inc. (NYSE:NIO) from Neutral to Outperform, citing better-than-expected fourth-quarter delivery figures and the growing success of its battery subscription model. The firm also increased its price target to $6.10.
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
Janus Henderson Group (NYSE:JHG) finds itself at the center of a valuation debate. While some models peg the asset manager as modestly undervalued, a deeper cash flow analysis suggests a starkly different picture, leaving investors to weigh competing narratives amid industry headwinds.
A new financial analysis suggests shares of UK property services group LSL could be trading at a significant discount to their estimated intrinsic value, presenting a potential opportunity for investors.
Jefferies raises price target on CS Disco following strong Q3 results fueled by its Cecilia AI platform, yet maintains a cautious 'Hold' rating as the company balances growth investments against profitability.
